Biodexa Pharmaceuticals Announces A Ratio Change On Its ADRs From 1 ADS Representing 400 Ordinary Shares, To The New Ratio Of 1 ADR Representing 10,000 Ordinary Shares (1-For-25) ; Effective Date Of The Ratio Change Is Expected To Be October 4,2024.
Biodexa Pharmaceuticals Announces A Ratio Change On Its ADRs From 1 ADS Representing 400 Ordinary Shares, To The New Ratio Of 1 ADR Representing 10,000 Ordinary Shares (1-For-25) ; Effective Date Of The Ratio Change Is Expected To Be October 4,2024.
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing four hundred (400) ordinary shares, to the new ratio of one (1) ADR representing ten thousand (10,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be October 4,2024.
Biodexa Pharmaceuticals PLC（納斯達克：BDRX）是一家以收購爲重點的臨床階段生物製藥公司，致力於爲治療未滿足醫療需求的疾病開發創新產品。今天，宣佈美國存託憑證（"ADR"）的比例變化，從每一份ADR代表四百（400）股普通股變更爲每一份ADR代表一萬（10,000）股普通股（"比例變化"）。比例變化的生效日期預計爲2024年10月4日。
Pursuant to the Ratio Change, ADR holders will be required on a mandatory basis to surrender their ADRs for cancellation and exchange to receive one (1) new ADR (New CUSIP: 59564R807) for every twenty-five (25) old ADRs (Old CUSIP: 59564R708). No fractional ADRs will be allocated. The aggregate fractions, if any, will be sold and the net proceeds will be distributed to the entitled ADR holder. The Company's Depositary, JP Morgan Chase Bank, N.A. will contact ADR holders and arrange for the exchange of their existing ADRs for new ADRs.
根據比例變化，ADR持有人將被要求強制性地交出其ADR以換取每二十五（25）箇舊ADR（舊CUSIP：59564R708）換取一（1）個新ADR（新CUSIP：59564R807）。不會分配任何零數ADR。如果有任何零數ADR，將會出售並將淨收益分配給有權ADR持有人。公司的託管銀行摩根大通銀行會聯繫ADR持有人，並安排交換其現有ADR爲新的ADR。